Clinical Edge Journal Scan

Elevated serum levels of thymic stromal lymphopoietin in patients with atopic dermatitis


 

Key clinical point: Serum levels of thymic stromal lymphopoietin (TSLP) are significantly elevated in patients with atopic dermatitis (AD), with the levels being significantly higher in adults than in children and increasing significantly corresponding to the severity of AD.

Major finding: Patients with AD vs control individuals had significantly higher serum levels of TSLP (standardized mean difference [SMD] 2.21; P < .001). Serum TSLP levels were significantly higher in adults vs children with AD ( P = .02) and had a significant positive association with AD severity (mild: SMD 1.15; P = .025; moderate: SMD 2.48; P = .024; severe: SMD 8.28; P = .000002).

Study details: The data come from a meta-analysis of 14 studies involving 1032 patients with AD and 416 control individuals without AD.

Disclosures: This study was funded by the Universidad Nacional Autónoma de México. The authors declared no conflicts of interest.

Source: García-Reyes MM et al. Serum thymic stromal lymphopoietin (TSLP) levels in atopic dermatitis patients: A systematic review and meta-analysis. Clin Exp Med. 2023 (Jul 29). doi: 10.1007/s10238-023-01147-5

Recommended Reading

Economic Burden and Quality of Life of Patients With Moderate to Severe Atopic Dermatitis in a Tertiary Care Hospital in Helsinki, Finland: A Survey-Based Study
MDedge Dermatology
Nemolizumab shows promise in pediatric atopic dermatitis with inadequately controlled pruritus
MDedge Dermatology
Amlitelimab is effective and well-tolerated in atopic dermatitis inadequately controlled by topical therapies
MDedge Dermatology
Continuous upadacitinib treatment required to maintain skin clearance in atopic dermatitis
MDedge Dermatology
Abrocitinib is safe and effective against difficult-to-treat atopic dermatitis in daily practice
MDedge Dermatology
Cannabis use is more prevalent in patients with atopic dermatitis
MDedge Dermatology
Early emollient bathing is tied to the development of atopic dermatitis by 2 years of age
MDedge Dermatology
Dupilumab + TCS confers rapid and sustained improvement in atopic dermatitis severity in children
MDedge Dermatology
Dupilumab maintains efficacy despite dose reduction in persistently-controlled atopic dermatitis
MDedge Dermatology
Long-term dupilumab therapy safe and effective in pediatric atopic dermatitis, shows meta-analysis
MDedge Dermatology